Page 4 - Pharmaceutical Firms

Largest Ibuprofen API maker eyes double revenue in next four years

As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio

Sanofi may underperform in near term; pricing control among key risks

The decline was largely on account of divestment of its nutraceutical business and a few key brands.

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Lupin pharmaceutical inks licensing pact with Japan-based I'rom Group

Drug maker Lupin on Thursday said it has inked a licensing pact with Japan-based I'rom Group Co for a product used in the treatment of postmenopausal women with osteoporosis, among others. Under the terms of the agreement, I'rom along with the Mumbai-based drugmaker will conduct clinical trials, register, distribute and market biosimilar Denosumab in Japan on an exclusive basis. Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumours, among other indications. Following the completion of the clinical trial and receipt of marketing authorisation in Japan, I'rom will commercialise the product in the island nation, Lupin said in a statement. As part of the agreement, the drug maker will receive multiple milestone payments, it added. Currently, Denosumab is available under two brands, Pralia and Ranmark, with market size of about USD 500 mill

DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Wockhardt reports Q1 net loss at Rs 75 cr as revenue from UK, US declines

Consolidated revenue from operations were at Rs 595 crore during the period under review, down from Rs 860 crore last year.

Aurobindo Pharma Q1 net profit down by 32% to Rs 520.5 cr; revenue up 9.4%

K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said, investments in product portfolio continued at a healthy pace as reflected in the filings and launches in the quarter."

100-year road map: Pharma industry eyes $400-billion turnover by 2047

The industry is now talking about breaking into the top-10 countries in terms of value by 2030, and entering the top-5 club by 2047

Pfizer buying spree continues with $5.4 billion hematology deal

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus

We're geared to launch a new molecule every 1-2 years: Biocon Biologics MD

In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

Cipla Q1 net dips 4% to Rs 686 cr, revenue down 2% on tapering Covid sales

Domestic revenue dips 8.4% as Covid-19 share of branded prescription business normalises; North American business up 10% to $155 million

Sun Pharma shares jump over 5% after firm's Q1 net profit rises 43%

Shares of Sun Pharma on Friday jumped over 5 per cent after the company reported a 43 per cent rise in consolidated net profit for the June quarter. The stock climbed 5.45 per cent to settle at Rs 943.55 apiece on the BSE. During the day, it rallied 6.31 per cent to Rs 951.25. On the NSE, it jumped 5.44 per cent to Rs 943.60 apiece. In volume terms, 4.88 lakh shares were traded on the BSE and over 1.13 crore shares on the NSE during the day. On Friday, Sun Pharma reported a 43 per cent rise in consolidated net profit at Rs 2,061 crore for the June quarter, riding on robust sales across markets. The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June period of 2021-22. Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing. The 30-share BSE barometer jumped 712.46 points or 1.25 per cent to settle at 57,570.25.

Alembic Pharma receive USFDA approval to market drug for skin treatment

Alembic Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market medication for treating actinic keratoses

Govt launches 3 schemes to strengthen MSMEs in pharmaceutical sector

The government on Thursday launched three schemes to strengthen Micro, Small and Medium Enterprises (MSMEs) in the pharmaceutical sector. Union minister Mansukh Mandaviya noted that the schemes envisage technology upgradation, setting up of common research centres and effluent treatment plants in clusters for the pharma MSMEs. Small companies should be able to upgrade their facilities to global manufacturing standards, he said. The chemicals and fertilisers ministry rolled out the schemes under the banner of 'Strengthening Pharmaceuticals Industry' (SPI). "I believe the pharma MSME industry will greatly benefit from the schemes. The new schemes have many benefits that will go a long way in making the Indian pharmaceutical industry, Atma Nirbhar, more resilient and future-ready," Mandaviya, who heads both health as well as chemical and fertilisers ministries, said. The schemes provide for credit linked capital and interest subsidy for technology upgradation of MSME units in ...

Amazon to buy primary care provider One Medical for $3.9 billion

Amazon announced it will acquire the primary care organisation One Medical in a deal valued roughly at USD 3.9 billion, marking another expansion for the retailer into health care services.

Rupee at 80: Neutral impact for India's pharma industry, say experts

India's pharma sector exported drugs worth Rs 1.8 trillion in 2021-22, while APIs worth Rs 30,000 crore were imported

Ahead of demerger, Piramal Pharma inducts three new board members

Piramal Enterprises has received shareholders' approval to demerge its Piramal Pharma business and simplify the corporate structure

Dolo-650 manufacturer faces raids by I-T dept in tax evasion case

A team of more than 20 officers associated with the I-T dept conducted the raids on the pharma company's Race Course Road office

Dr Reddy's says it aims to triple reach to 1.5 bn patients by 2030

Under its sustainability goals for the next decade, Dr Reddy's said it is making its "products accessible and affordable for patients" and "25 per cent of new launches to be first to market by 2027"